Longitude Capital

Portfolio · 2

Venus Concept

RF-based Technology for the Medical Aesthetics Market

2 rounds $31.0M committed Latest: 2019-11

89bio

Treatment for Liver and Metabolic Disorders

1 round $60.0M committed Latest: 2018-10

Investment activity

2 portfolio exits on record.

Q&A

What is Longitude Capital's primary sector focus for investments?

Longitude Capital primarily focuses its investments within the Health Tech & Life Sciences sector, with all of its portfolio companies and exits concentrated in this area.

Can you name some notable portfolio companies of Longitude Capital?

Longitude Capital's portfolio includes 89bio, which focuses on treatments for liver and metabolic disorders, and Venus Concept, a company utilizing RF-based technology for the medical aesthetics market.

Has Longitude Capital had any notable exits recently?

In November 2019, Longitude Capital had two notable exits through Public Offerings (POEvents) on NASDAQ: 89bio and Venus Concept. 89bio raised $85M during its POEvent.

What is the typical investment range for Longitude Capital?

Longitude Capital typically invests in the range of $10M to $60M.

When was Longitude Capital founded?

Longitude Capital was founded in 2019.

What is the most recent investment activity by Longitude Capital?

Longitude Capital's most recent recorded investment activity was in November 2019, which included a PIPE round.